Literature DB >> 30115629

CDK4/6 Inhibitors: What Is the Best Cocktail?

Marcos Malumbres1.   

Abstract

CDK4/6 inhibitors have shown great potential in the new armamentarium against cancer. However, their effect as single agents is limited, and the hopes are on new combinatory strategies. Recent data suggest that inhibiting mTOR may significantly cooperate with cell-cycle arrest in a variety of cancers.See related article by Song et al., p. 403. ©2018 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30115629     DOI： 10.1158/1078-0432.CCR-18-2177

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  8 in total

Review 1.  Mechanisms of resistance to estrogen receptor modulators in ER+/HER2- advanced breast cancer.

Authors:  Jin Zhang; Qianying Wang; Qing Wang; Jiangran Cao; Jiafu Sun; Zhengmao Zhu
Journal:  Cell Mol Life Sci       Date:  2019-08-30       Impact factor: 9.261

2.  Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in adult T-cell leukemia/lymphoma.

Authors:  Takashi Ishio; Sarvesh Kumar; Joji Shimono; Anusara Daenthanasanmak; Sigrid Dubois; Yuquan Lin; Bonita Bryant; Michael N Petrus; Emmanuel Bachy; Da Wei Huang; Yandan Yang; Patrick L Green; Hiroo Hasegawa; Michiyuki Maeda; Hideki Goto; Tomoyuki Endo; Takashi Yokota; Kanako C Hatanaka; Yutaka Hatanaka; Shinya Tanaka; Yoshihiro Matsuno; Yibin Yang; Satoshi Hashino; Takanori Teshima; Thomas A Waldmann; Louis M Staudt; Masao Nakagawa
Journal:  Blood       Date:  2022-03-10       Impact factor: 22.113

3.  Palbociclib-based high-throughput combination drug screening identifies synergistic therapeutic options in HPV-negative head and neck squamous cell carcinoma.

Authors:  Ziyue Gu; Chaoji Shi; Jiayi Li; Yong Han; Bao Sun; Wuchang Zhang; Jing Wu; Guoyu Zhou; Weimin Ye; Jiang Li; Zhiyuan Zhang; Rong Zhou
Journal:  BMC Med       Date:  2022-05-12       Impact factor: 11.150

4.  The Acquired Vulnerability Caused by CDK4/6 Inhibition Promotes Drug Synergism Between Oxaliplatin and Palbociclib in Cholangiocarcinoma.

Authors:  Orawan Suppramote; Sunisa Prasopporn; Satinee Aroonpruksakul; Ben Ponvilawan; Jiradej Makjaroen; Monthira Suntiparpluacha; Krittiya Korphaisarn; Komgrid Charngkaew; Rawisak Chanwat; Trairak Pisitkun; Seiji Okada; Somponnat Sampattavanich; Siwanon Jirawatnotai
Journal:  Front Oncol       Date:  2022-05-17       Impact factor: 5.738

Review 5.  Targeting cell-cycle machinery in cancer.

Authors:  Jan M Suski; Marcin Braun; Vladislav Strmiska; Piotr Sicinski
Journal:  Cancer Cell       Date:  2021-04-22       Impact factor: 38.585

6.  Stapled peptide targeting the CDK4/Cyclin D interface combined with Abemaciclib inhibits KRAS mutant lung cancer growth.

Authors:  Celine Bouclier; Matthieu Simon; Guillaume Laconde; Morgan Pellerano; Sebastien Diot; Sylvie Lantuejoul; Benoit Busser; Laetitia Vanwonterghem; Julien Vollaire; Véronique Josserand; Baptiste Legrand; Jean-Luc Coll; Muriel Amblard; Amandine Hurbin; May C Morris
Journal:  Theranostics       Date:  2020-01-12       Impact factor: 11.556

7.  FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1.

Authors:  Miguel Quintela-Fandino; Maria J Bueno; Silvana Mouron; Luis Manso; Eduardo Caleiras; Jose L Rodriguez-Peralto; Oscar M Rueda; Carlos Caldas; Ramon Colomer
Journal:  Breast Cancer Res       Date:  2021-02-12       Impact factor: 6.466

8.  Enhancing CDK4/6 inhibitor therapy for medulloblastoma using nanoparticle delivery and scRNA-seq-guided combination with sapanisertib.

Authors:  Chaemin Lim; Taylor Dismuke; Daniel Malawsky; Jacob D Ramsey; Duhyeong Hwang; Virginia L Godfrey; Alexander V Kabanov; Timothy R Gershon; Marina Sokolsky-Papkov
Journal:  Sci Adv       Date:  2022-01-26       Impact factor: 14.136
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.